NeuroMetrix Surges 33% After Quell Wearable Neuromodulation Device Gets FDA De Novo Authorization

JetBlue Says Spirit Distorting Facts To Ignore Best Interests Of Its Shareholders

Following the unanimous rejection of the unsolicited tender offer from JetBlue Airways Corp. (JBLU) by Spirit Airlines, Inc. (SAVE) on Thursday, JetBlue hit back immediately saying the Spirit Board, driven by serious conflicts of interest, continues to ignore the best interests of its shareholders by distorting the facts to protect their inferior deal with Frontier Airlines, Inc. (FRNT).

JetBlue said both deals are subject to regulatory review, and both deals have a similar risk profile. It added that Spirit shareholders recognize that and are showing great interest in hearing more about our superior offer and the regulatory commitments and protections JetBlue has made, including a reverse break-up fee.

JetBlue noted that Frontier offers less value, more risk, and no regulatory commitments, despite a similar regulatory profile.

JetBlue believes that the Spirit shareholders will make their views known by voting against the Frontier offer and tendering their shares into its offer.

Moderna Rally Persists

Moderna, Inc. (MRNA) shares are gaining more than 5 percent on Thursday after the company, continuing an upsurge since May 11. There were no corporate announcements on the day to support the stock movement.

Currently, shares are at $144.05, up 5 percent from the previous close of $137.71 on a volume of 1,879,205. For the 52-week period, the shares have traded in a range of $119.01-$497.49 on average volume of 7,168,996.

Bilibili Shares Rise 6%; Maintain Upward Tick

Shares of video-streaming platform Bilibili Inc. (BILI) are rising 6 percent on Thursday’s trading, continuing their upward movement since Wednesday.

While there is no company announcement to influence the stock, it was recently upgraded from an “underweight” rating to a “neutral” rating by analysts, as per reports.

Currently at $21.86, the stock has traded between $14.93 and $129.24 during the past 52 weeks.

CBAK Energy Technology Gains On Surge In Q1 Revenue

CBAK Energy Technology, Inc. (CBAT) shares are gaining more than 6 percent on Thursday morning trade after the company reported a surge in first-quarter revenue, compared to the prior year.

The lithium-ion battery manufacturer and electric energy solution provider reported first-quarter net revenue of $80.2 million, up 752 percent from $9.4 million in the prior year. The company said the acquisition of Hitrans and strong sales of high-power lithium batteries supported the revenue growth.

Currently, shares are at $1.12, up 6 percent from the previous close of $1.07 on a volume of 8,049,694. For the 52-week period, the shares have traded in a range of $0.92-$5.10 on average volume of 960,198.

David Fincher Tries Animation in ‘Love, Death + Robots’

The director made his first animated short for the new season of this Netflix anthology. “It was an incredibly freeing, eye-opening, mind-expanding way to interface with a story,” he said.

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Noel Murray

‘Mondocane’ Review: Fractured Friendship, Fractured World

Two orphaned boys fall in with a criminal gang in this post-apocalyptic thriller.

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Jeannette Catsoulis

When you purchase a ticket for an independently reviewed film through our site, we earn an affiliate commission.

Chinook Therapeutics Stock Gains 8%

Shares of Chinook Therapeutics, Inc. (KDNY) are gaining over 8% on Thursday morning. The company presented updated data from BION-1301 phase 1/2 trial in patients with IgA Nephropathy.

KDNY is currently trading at $13.70, up $1.11 or 8.82%, on the Nasdaq.

Chinook Therapeutics announced three mini-oral presentations on the BION-1301 and atrasentan clinical programs at the 59th ERA Congress 2022 being held virtually and live in Paris, France.

“The additional data we presented today at ERA from the ongoing phase 1/2 study of BION-1301 further demonstrates its disease-modifying potential in IgAN by generating durable reductions in mechanistic biomarkers and corresponding impressive proteinuria reductions within three months of initiating treatment,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. “IgAN is a serious progressive disease for which there are limited treatment options, and the data from this trial will inform the design of a phase 3 trial of BION-1301 for patients with IgAN that we plan to initiate in 2023.”

‘The Valet’ Review: A Crowd Pleasing Buddy Comedy

What seems like a standard rom-com takes a spin in a different direction.

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Beandrea July

When you purchase a ticket for an independently reviewed film through our site, we earn an affiliate commission.

NeuroMetrix Surges 33% After Quell Wearable Neuromodulation Device Gets FDA De Novo Authorization

Shares of NeuroMetrix, Inc. (NURO) are gaining over 33% on Thursday morning after the company reported that its Quell wearable neuromodulation device received FDA De Novo authorization as first non-pharmacological treatment for fibromyalgia.

NURO is currently trading at $4.1801, up $1.0601 or 33.9776%, on the Nasdaq. The stock opened its trading at $4.66 after closing Wednesday’s trading at $3.12. The stock has traded between $2.70 and $38.75.

NeuroMetrix announced FDA De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021.

Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory and concentration impairments, mood disorders and other disabling symptoms. These individuals experience low health-related quality of life and are twice as likely to be hospitalized as someone without fibromyalgia.